Drug induced bradycardia: To pace or not to pace?

PACE - Pacing and Clinical Electrophysiology

Volumn 27, Issue 8, 2004, Pages 1144-1147

  Ovsyshcher, I Eli ^a,c   Barold, S Serge ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARBAMAZEPINE; CARVEDILOL; CIMETIDINE; COCAINE; DIGITALIS; DIGOXIN; DISOPYRAMIDE; FLECAINIDE; INOTROPIC AGENT; ISOPRENALINE; LITHIUM; METOPROLOL; OPIATE ANTAGONIST; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; TEDISAMIL; VERAPAMIL;

ANGINA PECTORIS; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DRUG INDUCED DISEASE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; REVIEW; SINUS ARREST; SINUS BRADYCARDIA; SINUS NODE DYSFUNCTION; SUPRAVENTRICULAR TACHYCARDIA;

ANGINA PECTORIS; ANTI-ARRHYTHMIA AGENTS; BRADYCARDIA; CARDIOMYOPATHY, HYPERTROPHIC; HEART FAILURE, CONGESTIVE; HUMANS; PACEMAKER, ARTIFICIAL; TACHYCARDIA, ECTOPIC ATRIAL;

EID: 4344678048     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2004.00597.x     Document Type: Review

References (21)

1. Gregoratos G, Abrams J, Epstein AE, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines American College of Cardiology/American Heart Association/North American Society for Pacing and Electrophysiology Committee. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002; 106:2145-2161.
2. Podrid PJ. Aggravation of arrhythmia by antiarrhythmic drugs. In PJ Podrid, PR Kowey (eds.): Cardiac Arrhythmia. Mechanisms, Diagnosis and Management. Baltimore, MD, Williams & Wilkins, 1995, pp. 507-522.
3. Friedman PL, Stevenson WG. Proarrhythmia. Am J Cardiol 1998; 82:50N-58N.
4. Zipes DP. Proarrhythmic effect of antiarrhythmic drugs. Am J Cardiol 1987; 59:26E-31E.
5. Stanton MS, Prystowsky EN, Fineberg NS, et al. Arrhythmogenic effects of antiarrhythmic drugs: A study of 506 patients treated for VT or fibrillation. J Am Coll Cardiol 1989; 14:209-215.
6. Hofman R, Leisch F. Symptomatic bradycardia with amiodarone in patients with pre-existing conduction disorders. Wien Klin Wochenschr 1995; 107:640-644.
7. Israel CW, Ehrlich JR, Barold SS, et al. Treatment of tachyarrhythmias with pacing and antiarrhythmic drugs. In CW Israel, SS Barold (eds.): Advances in the Treatment of Atrial Tachyarrhythmias: Pacing, Cardioversion, and Defibrillation. Armonk, NY, Futura 2002, pp. 305-323.
8. Yusuf S, Camm AJ. Sinus tachyarhythmias and the specific bradycardia agents: A marriage made in haven? J Cardiovasc Pharmacol Ther 2003; 8:89-105.
9. Hauser TH, Pinto DS, Josephson ME, et al. Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter. Am J Cardiol 2003; 91:1437-1441.
10. Essebag V, Hadjis T, Platt RW, et al. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol 2003; 15:249-254.
11. Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial fibrillation required? J Am Coll Cardiol 1998; 32:169-176.
12. Crystal E, Ovsyshcher IE. Atrial pacing algorithms for the prevention of atrial fibrillation. In M Gulizia (ed.): New Advances in Heart Failure and Atrial Fibrillation. Milan, Springer, 2003, pp. 343-350.
13. Savelieva I, Camm AJ. The results of pacing trials for the prevention and termination of atrial tachyarrhythmias: Is there any evidence of therapeutic breakthrough? J Interv Card Electrophysiol 2003; 8:103-115.
14. Ovsyshcher IE, Barold SS. Cardiac pacing in patients with marked first-degree AV block. In IE Ovsyshcher (ed.): Cardiac Arrhythmias and Device Therapy: Results and Perspectives for the New Century. Armonk, NY, Futura Publishing Company, Inc., 2000, pp. 409-417.
15. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Mode Selection Trial Investigators. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003; 107:2932-2937.
16. Ovsyshcher IE. Towards physiological pacing: Optimization of cardiac hemodynamics by AV delay adjustment. PACE 1997; 20:861-865.
17. Wilkoff BL, Cook JR, Epetein AE, et al. Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288:3115-3123.
18. Leclercq C, Kass DA. Retiming the failing heart: Principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol 2002; 39:194-201.
19. Gasparini M, Mantica M, Galimberti P, et al. Relief of drug refractory angina by biventricular pacing in heart failure. PACE 2003; 26:181-184.
20. Barold SS, Barold HS. Optimal cardiac pacing in patients with coronary artery disease. PACE 1998; 21:456-461.
21. Englund A, Bergfeldt L, Rosenqvist M. Pharmacological stress testing of the His-Purkinje system in patients with bifascicular block. PACE 1998; 21:1979-1987.